Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $87.8 million.

  • Stoke Therapeutics' Non-Current Assets rose 12118.77% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $272.3 million, marking a year-over-year increase of 26125.76%. This contributed to the annual value of $38.8 million for FY2024, which is 19838.5% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Non-Current Assets is $87.8 million, which was up 12118.77% from $114.5 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Non-Current Assets peaked at $114.5 million during Q2 2025, and registered a low of $9.9 million during Q3 2023.
  • Over the past 4 years, Stoke Therapeutics' median Non-Current Assets value was $12.3 million (recorded in 2022), while the average stood at $28.5 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first plummeted by 2422.26% in 2023, then surged by 96418.28% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Non-Current Assets (Quarter) stood at $12.0 million in 2022, then increased by 8.39% to $13.0 million in 2023, then skyrocketed by 198.38% to $38.8 million in 2024, then surged by 126.36% to $87.8 million in 2025.
  • Its Non-Current Assets was $87.8 million in Q3 2025, compared to $114.5 million in Q2 2025 and $31.2 million in Q1 2025.